Top

Published in:

01-12-2016 | Original Article

Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration’s Mini-Sentinel program

Authors: Susan E. Andrade, Marsha E. Reichman, Katrina Mott, Marilyn Pitts, Caren Kieswetter, Miriam Dinatale, Marc B. Stone, Jennifer Popovic, Katherine Haffenreffer, Sengwee Toh

Published in: Archives of Women's Mental Health | Issue 6/2016

Abstract

This study was conducted in order to assess the prevalence of use of selective serotonin reuptake inhibitors (SSRIs) among pregnant women delivering a liveborn infant in the USA. A retrospective study was conducted using the automated databases of 15 health-care systems participating in the Mini-Sentinel program. Diagnosis and procedure codes were used to identify women ages 10 to 54 years delivering a liveborn infant between April 2001 and December 2013. A comparison group of age- and date-matched women without live births was identified. The frequency of use of SSRIs was identified from outpatient dispensing data. Among the 1,895,519 liveborn deliveries, 113,689 women (6.0 %) were exposed to an SSRI during pregnancy during the period 2001–2013; 5.4 % were exposed to an SSRI during 2013. During the corresponding time period, 10.5 % of the age- and date-matched cohort of women without live births was exposed to an SSRI, with 10.1 % exposed to an SSRI during 2013. The most common agents dispensed during pregnancy were sertraline (n = 48,678), fluoxetine (n = 28,983), and citalopram (n = 20,591). Among those women exposed to an SSRI during pregnancy, 53.8 % had a diagnosis of depression and 37.3 % had a diagnosis of an anxiety disorder during pregnancy or within 180 days prior to pregnancy. Our finding that 6 % of women with live births were prescribed SSRIs during pregnancy highlights the importance of understanding the differential effects of these medications and other therapeutic options on the developing fetus and on the pregnant women.

Available only for authorised users

Andrade SE, Davis RL, Cheetham TC et al (2012) Medication exposure in pregnancy risk evaluation program. Matern Child Health J 16:1349–1354CrossRefPubMedPubMedCentral

Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198:194.e1–194.e5CrossRef

Andrade SE, Toh S, Houstoun M et al (2016) Surveillance of medication use during pregnancy in the Mini-Sentinel program. Matern Child Health J 20(4):895–903CrossRefPubMed

Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R (2011) Developing the Sentinel System—a national resource for evidence development. N Engl J Med 364:498–499CrossRefPubMed

Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698–709CrossRefPubMed

Bobo WV, Epstein RA Jr, Hayes RM, Shelton RC, Hartert TV, Mitchel E, Horner J, Wu P (2014) The effect of regulatory advisories on maternal antidepressant prescribing, 1995–2007: an interrupted time series study of 228,876 pregnancies. Arch Womens Ment Health 17:17–26CrossRefPubMed

Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G (2004) Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49:726–735PubMed

Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196:544.e1–544.e5CrossRef

Curtis LH, Weiner MG, Boudreau DM et al (2012) Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf 21(Suppl 1):23–31CrossRefPubMed

Gavin NI, Gaynes BN, Lohr KN, Melzer-Brody S, Gartlehner G, Swinson T (2005) Perinatal depression. Obstet Gynecol 106:1071–1083CrossRefPubMed

Gentile S (2011) Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 123:266–275CrossRefPubMed

Huybrechts KF, Palmsten K, Mogun H et al (2013) National trends in antidepressant medication treatment among publicly-insured pregnant women. Gen Hosp Psychiatry 35(3):265–271CrossRefPubMedPubMedCentral

Kawai AT, Li L, Kulldorff M, et al. (2014) Mini-Sentinel CBER/PRISM surveillance protocol influenza vaccines and pregnancy outcome. Version 2. http://www.mini-sentinel.org/work_products/PRISM/Mini-Sentinel_PRISM_Influenza-Vaccines-and-Pregnancy-Outcomes-Protocol.pdf. Accessed 8 Sept 2015

Le Strat Y, Dubertret C, Le Foll B (2011) Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord 135:128–138CrossRefPubMed

Li Q, Andrade SE, Cooper WO et al (2013) Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiol Drug Saf 22:524–532CrossRefPubMedPubMedCentral

Melville JL, Gavin A, Guo Y, Fan MY, Katon WJ (2010) Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. Obstet Gynecol 116:1064–1070CrossRefPubMedPubMedCentral

Meunier MR, Bennett IM, Coco AS (2013) Use of antidepressant medication in the United States during pregnancy, 2002–2010. Psychiatr Serv 64:1157–1160CrossRefPubMed

Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, National Birth Defects Prevention Study (2011) Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol 205:51.e1–51.e8CrossRef

Myles N, Newall H, Ward H, Large M (2013) Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 47:1002–1012CrossRefPubMed

Platt R, Carnahan RM, Brown JS et al (2012) The U.S. Food and Drug Administration’s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 21(Suppl 1):1–8PubMed

Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, National Birth Defects Prevention Study (2015) Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 351:h3190CrossRefPubMedPubMedCentral

Rosati K, Evans B, McGraw D (2011) HIPAA and common rule compliance in the Mini-Sentinel pilot, white paper. http://www.mini-sentinel.org/work_products/About_Us/HIPAA_and_CommonRuleCompliance_in_the_Mini-SentinelPilot.pdf [serial online]. Accessed 8 Sept 2015

U.S. Food and Drug Administration (2004) FDA Medwatch drug alert on Effexor and SSRIs. June 3, 2004. Effexor and Effexor XR (venlafaxine HCl) http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154975.htm. Accessed 8 Sept 2015

U.S. Food and Drug Administration (2005) FDA public health advisory: paroxetine. December 8, 2005. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051731.htm. Accessed 8 Sept 2015

U.S. Food and Drug Administration (2006) FDA alert [7/2006]: increased risk of neonatal persistent pulmonary hypertension. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085313.htm. Accessed 8 Sept 2015

U.S. Food and Drug Administration (2011) FDA drug safety communication: selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. December 14, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. Accessed 8 Sept 2015

Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C (2009) The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 114:703–713CrossRefPubMedPubMedCentral

Title: Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration’s Mini-Sentinel program
Authors: Susan E. Andrade
Marsha E. Reichman
Katrina Mott
Marilyn Pitts
Caren Kieswetter
Miriam Dinatale
Marc B. Stone
Jennifer Popovic
Katherine Haffenreffer
Sengwee Toh
Publication date: 01-12-2016
Publisher: Springer Vienna
Published in: Archives of Women's Mental Health / Issue 6/2016
Print ISSN: 1434-1816
Electronic ISSN: 1435-1102
DOI: https://doi.org/10.1007/s00737-016-0637-1

At a glance: The STEP trials

Springer Medicine

Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration’s Mini-Sentinel program

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Schizophrenia in Women—A Different Phenotype?

Anxiety, depression, and quality of life in mothers of newborns with microcephaly and presumed congenital Zika virus infection

Prevalence, continuation, and identification of postpartum depressive symptomatology among refugee, asylum-seeking, non-refugee immigrant, and Canadian-born women: results from a prospective cohort study

Development of a mother and baby unit contraception assessment tool

Suicidality in early pregnancy among antepartum mothers in urban India

Vulnerability to intimate partner violence and poor mental health in the first 4-year postpartum among mothers reporting childhood abuse: an Australian pregnancy cohort study